“Global Pulmonary/Respiratory Drug Delivery market set to grow to $62bn by 2024” says new Visiongain report

29 May 2019
Pharma

Visiongain has launched a new pharma report Global Respiratory Drug Delivery Market: Suspension Aerosol, Solution Aerosol, Dry Powder Formulation, Metered Dose Inhalers (MDIS), Dry Powder Inhalers (DPIS), Nebulizers, Accessories, Plain Canister, Coated Canister, Asthma, COPD, Cystic Fibrosis, Other Applications, Hospitals & Clinics, Homecare Settings.

The global pulmonary/respiratory drug delivery market reached $40.67 bn in 2018 and is expected to grow at a CAGR of 7.60% in 2019-2024. The MDIs segment is estimated to hold a share of 62.4% in 2018. Increasing prevalence and incidence of chronic respiratory diseases is a major factor that is expected to drive the growth of this market.

The lead analyst of the report commented "Technological advances in drug delivery will have a positive impact on the market for pulmonary drug delivery devices. These advances include the electronic dose counter MDI, incorporation of agglomerated vesicle technology, and technology for supercritical fluids. Moreover, increasing demand for advanced drug delivery devices, improving healthcare infrastructure, ease of use, and increase in healthcare spending are some of the major factors that will provide lucrative opportunities in the near future."

Leading companies featured in the report include AstraZeneca, Boehringer Ingelheim GmbH, GlaxoSmithKline PLC, Novartis AG, OMRON Corporation, Sunovion Pharmaceuticals Inc., Teva and other companies

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 20 7549 9987.

About Visiongain
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Ophthalmic Devices Market Report 2022-2032

The number of people who are blind or have poor vision is expected to rise considerably in the coming years. The growing elderly population is one of the key drivers of the Ophthalmic Devices Market’s upward trend.

19 April 2022

Read

Visiongain Publishes Vaccine Contract Manufacturing Market Report 2022-2032

The growing global health system has made significant contributions to protecting and promoting human health. However, long-standing, developing, and reemerging infectious disease risks continue to plague the planet

13 April 2022

Read

Visiongain Publishes Pharmaceutical Contract Manufacturing Market Report 2022-2032

The major driving factor contributing towards the growth of pharmaceutical contract manufacturing market are increase in investments in pharmaceutical R&D, rise in number of patent expiry, rising demand of generic drugs, and investment in advanced manufacturing technologies. However, use of serialization can thwart the market growth.

13 April 2022

Read

Visiongain Publishes Vaccine Sales Market Report 2022-2032

Rising epidemic potential, a growing emphasis on therapeutic vaccines, and new markets are projected to provide considerable growth prospects for vaccine providers.

30 March 2022

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever